U.S. Medicine Magazine has highlighted CyPath® Lung, a noninvasive diagnostic test developed by bioAffinity Technologies, as a promising tool to enhance lung cancer detection among veterans while reducing costs for the Department of Veterans Affairs (VA). The feature underscores the test’s potential to improve clinical outcomes and streamline care for veterans at high risk of developing lung cancer. Maria Zannes, President and CEO of bioAffinity Technologies, expressed pride in the recognition, stating that integrating CyPath® Lung into standard care can reduce system-wide costs and provide clinicians with a valuable tool to resolve diagnostic uncertainty. The test uses advanced flow cytometry and artificial intelligence to analyze cell populations in patient sputum, identifying signs of malignancy with high accuracy. A recent study published in the Journal of Health Economics and Outcomes Research (JHEOR), co-authored by Michael J. Morris, M.D., of Brooke Army Medical Center, and Sheila A. Habib, M.D., of the South Texas Veterans Health Care System, modeled the economic impact of adopting CyPath® Lung in 2022. The analysis projected nearly $895 million in savings for private payers and $379 million for Medicare, primarily due to fewer unnecessary follow-up procedures and reduced diagnostic delays. Clinical data shows CyPath® Lung achieves 92% sensitivity, 87% specificity, and 88% overall accuracy in detecting lung cancer in high-risk patients with small pulmonary nodules (20 mm or smaller). In real-world case studies, the test successfully identified early-stage lung cancer—specifically Stage 1A—when other methods like PET/CT scans, blood markers, and risk models failed to suggest malignancy. With increasing numbers of veterans undergoing lung cancer screening, the number of small pulmonary nodules detected by imaging continues to grow. This presents a clinical challenge: balancing the need for early detection with the risks and costs of invasive follow-up procedures. The JHEOR study concluded that incorporating companion diagnostics like CyPath® Lung can improve patient triage, reduce diagnostic delays, and lead to better prognoses. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. The test uses a fluorescent porphyrin that selectively accumulates in cancer and cancer-related cells, enabling precise detection through automated AI-driven analysis. As early detection significantly improves survival rates, the integration of CyPath® Lung into standard care could transform lung cancer screening for veterans and other high-risk populations. For more information, visit www.cypathlung.com. bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) is focused on noninvasive early cancer detection and broad-spectrum cancer therapies. The company continues to advance its pipeline with the goal of improving outcomes and reducing healthcare burdens. Forward-looking statements in this release are based on current expectations and involve risks and uncertainties. Actual results may differ materially due to factors including test performance, regulatory developments, market adoption, and other risks detailed in the company’s SEC filings. The company does not undertake any obligation to update these statements except as required by law.